Vantictumab: Phase Ib data

Top-line data from 21 evaluable patients with locally recurrent or metastatic HER2-negative breast cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed

Read the full 239 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE